NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: Guggenheim SMID Cap Biotech Conference – Fireside chat on February ...

Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune and inflammatory diseases [3] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [3] - Dianthus Therapeutics is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency [3] Upcoming Event - Dianthus Therapeutics will participate in the 43rd Annual J P Morgan Healthcare Conference [1] - CEO Marino Garcia will present a corporate overview on January 15, 2025, at 9:00 a m PST / 12:00 p m EST in San Francisco [1] - A live webcast of the presentation will be available on the company's website under the "News and Events" section in the Investors section [2] Additional Information - More details about Dianthus Therapeutics can be found on their website at www dianthustx com [4] - The company can also be followed on LinkedIn for updates [4]

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.42%. A quarter ago, it was expected that this company would post a loss of $0.50 per share when it actually produced a loss of $0.51, delivering a surprise of -2%.Over the last four quarters, the company ha ...

NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conferenc ...

Dianthus Therapeutics, Inc. (DNTH) shares soared 5.7% in the last trading session to close at $27.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.9% loss over the past four weeks. The growing optimism over the company's lead pipeline candidate DNTH103, which is being developed for treating several autoimmune diseases, like generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN) and chronic inflammatory demyel ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.54, delivering a surprise of -25.58%. Over the last four quarters, the company ...

Its lead investigational candidate is DNTH103, which is being developed for several autoimmune indications, like generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). DNTH103 is a monoclonal antibody in clinical development. It is designed to selectively inhibit the active form of the C1s protein, a vital component of the classical complement pathway, which has been clinically validated as a therapeutic target for autoimmune dise ...

leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn. Cautionary Statement Regarding Forward-Looking Statements Certain statements in this press release, other than purely historical information, may constitute "forwardlooking statements" within the meaning of the federal securities laws, including for ...

DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. Dianthus Presentations at EAN: June 30, 2024, 14:25 EEST "Currently, therapies for patients with generalized Myasthenia Gravis (gMG) are limited to C5 inhibitors ...

Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Recently disclosed head-to-head affinity and PD potency data reinforce DNTH103 is a highly potent, potential best-in-class active C1s inhibitor designed for self-administration in a low-volume, subcutaneous autoinjector once every two weeks "Pre-clinical and clinical evidence support the classical pathway's role in the pathology seen in MMN," said Simrat Randhawa, MD, Chief Medical Officer of Dianthus Therapeu ...